亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

武漢百茂生物科技有限公司  

食品添加劑,醫(yī)藥原料,提取物,飼料添加劑,香精香料

搜索
新聞中心
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:劉志云
  • 電話:027-50756019
  • 郵件:ycsales03@ycphar.com
  • 傳真:027-68886696-884
  • QQ:2355880527
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 廠家直銷***萘甲唑啉
廠家直銷***萘甲唑啉
單價 1080.00 / kg對比
詢價 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
庫存 10000kg
品牌 bm
過期 長期有效
更新 2014-04-19 10:10
 
詳細信息
***萘甲唑啉
英文名:Naphazoline Hydrochloride
別稱:***萘唑啉、鼻眼凈、滴鼻凈、***納發(fā)唑啉
分子式:C14H14N2.HCl
分子量:246.74
CAS號:550-99-2
性狀:白色結(jié)晶性粉末。在100毫升水中可溶解本品40克。易溶于乙醇,微溶于氯仿,無臭,味苦。
含量:99%
熔點:254-260°C
包裝:25KG紙桶
用途:本品為α-受體激動劑,具有收縮鼻粘膜血管作用,減少血管的滲出物,減輕鼻粘膜腫脹充血。臨床用于治傷風(fēng)過敏性鼻炎、炎癥性鼻充血、急慢性鼻炎。
銷售價:1080元/KG

©2025 武漢百茂生物科技有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:5221  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |